Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-A01042-43 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
to compare the efficacy of HIFU treatment with standard treatment in two situations:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIFU | Experimental | Patients Treated with high intensity focused ultrasound (HIFU) |
|
| Prostatectomy | Active Comparator | Patients Treated by Radical Prostatectomy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radical Prostatectomy | Procedure | The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA > 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days. |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence-free survival | The main objective for patients is to compare recurrence-free survival (i.e., the rate of salvage therapy by external beam radiotherapy and/or hormone therapy) in patients treated by HIFU and those treated by radical prostatectomy. The implementation of salvage therapy will be decided according to several non-exclusive criteria (positivity of margins (for patients with radical prostatectomy), PSA at 3 months, biologic recurrence (increase in PSA > 0.2 ng/ml after radical surgery, > Nadir +2 after HIFU), control biopsies positive, the appearance of metastases | 30 months |
| Measure | Description | Time Frame |
|---|---|---|
| Immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 6 weeks after treatment |
| Immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) |
Not provided
General inclusion criteria
Inclusion criteria for the HIFU Arm
Inclusion Criteria for Total Prostatectomy Arm
• Patients with a life expectancy greater than 10 years and a state of health allowing general anaesthesia.
NON-INCLUSION CRITERIA
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier d'Aix en Provence | Aix-en-Provence | 13616 | France | |||
| Polyckinique du Beaujolais |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42055879 | Derived | Ploussard G, Coloby P, Chevallier T, Occean BV, Kassab D, Houede N, Villers A, Rischmann P. Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study). Eur Urol Oncol. 2026 Apr 28:S2588-9311(26)00112-4. doi: 10.1016/j.euo.2026.04.007. Online ahead of print. | |
| 39632125 | Derived |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| High Intensity Focused Ultrasound (HIFU) Treatment | Procedure | The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime. |
|
| Day 0, Inclusion |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 3 months after treatment |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 6 months after treatment |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 12 months after treatment |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 18 months after treatment |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 24 months after treatment |
| immediate or late complications | clinical observations (Stenosis, bleeding, hemorrhoids, urinary infections ...) | 30 months after treatment |
| urinary function | measured by the International Prostate Symptom score (IPSS). For the first seven questions: 0 to 7: mild disorders, 8 to 19: moderate disorders, 20 to 35: severe disorders For quality of life question 8: Score from 0 to 6: 0 no discomfort, 6 very discomfort | Day 0, Inclusion |
| urinary function | measured by the International Prostate Symptom score (IPSS). For the first seven questions: 0 to 7: mild disorders, 8 to 19: moderate disorders, 20 to 35: severe disorders For quality of life question 8: Score from 0 to 6: 0 no discomfort, 6 very discomfort | 6 months after treatment |
| urinary function | measured by the International Prostate Symptom score (IPSS). For the first seven questions: 0 to 7: mild disorders, 8 to 19: moderate disorders, 20 to 35: severe disorders For quality of life question 8: Score from 0 to 6: 0 no discomfort, 6 very discomfort | 12 months after treatment |
| urinary function | measured by the International Prostate Symptom score (IPSS). For the first seven questions: 0 to 7: mild disorders, 8 to 19: moderate disorders, 20 to 35: severe disorders For quality of life question 8: Score from 0 to 6: 0 no discomfort, 6 very discomfort | 24 months after treatment |
| urinary function | measured by the International Prostate Symptom score (IPSS). For the first seven questions: 0 to 7: mild disorders, 8 to 19: moderate disorders, 20 to 35: severe disorders For quality of life question 8: Score from 0 to 6: 0 no discomfort, 6 very discomfort | 30 months after treatment |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | Day 0, Inclusion |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | 6 months after treatment |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | 12 months after treatment |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | 18 months after treatment |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | 24 months after treatment |
| urinary function | Urinary function measured by the International Continence Society score (ICS score). Question 1: Stress incontinence Score (frequency) from 0 to 4 (never - always) Sub-score 1a (quality of life) from 0 to 3 (none - significant discomfort) Question 2: Insensitive incontinence Score (frequency) from 0 to 4 (never - always) Sub score 2 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 3: Incontinence at night Score (frequency) from 0 to 4 (never - always) Sub score 3 bis (quality of life) from 0 to 3 (none - significant discomfort) Question 4: Change of clothing or protective wear Score from 0 to 4 (no leakage of urine - seal port) Sub-score 4 bis (quality of life) from 0 to 3 (no significant discomfort to major discomfort) Question 5: Number of protection used Day Score: 0 to 4 (none to 6 or more) Score at night: 0 to 4 (none to 6 or more) Translated with www.DeepL.com/Translator (free version) | 30 months after treatment |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | Day 0, Inclusion |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | 6 months after treatment |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | 12 months after treatment |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | 18 months after treatment |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | 24 months after treatment |
| urinary function | Urinary function measured by the Urinary Symptom Score(USP). 3 sub-scores: stress urinary incontinence score: 0 to 9 (none - significant) OAB score: 0 to 21(none - significant) Dysuria score: 0 to 9 (none - significant) | 30 months after treatment |
| sexual fonction | Sexual function results are measured by the International Index Erectile Function score (IIEF-5). score from 1 to 4: not interpretable score from 5 to 10: severe erectile dysfunction score from 11 to 15: moderate erectile dysfunction score from 16 to 20: mild erectile dysfunction score from 21 to 25: normal erectile function | Day 0, Inclusion |
| sexual fonction | Sexual function results are measured by the International Index Erectile Function score (IIEF-5). score from 1 to 4: not interpretable score from 5 to 10: severe erectile dysfunction score from 11 to 15: moderate erectile dysfunction score from 16 to 20: mild erectile dysfunction score from 21 to 25: normal erectile function | 6 months after treatment |
| sexual fonction | Sexual function results are measured by the International Index Erectile Function score (IIEF-5). score from 1 to 4: not interpretable score from 5 to 10: severe erectile dysfunction score from 11 to 15: moderate erectile dysfunction score from 16 to 20: mild erectile dysfunction score from 21 to 25: normal erectile function | 12 months after treatment |
| sexual fonction | Sexual function results are measured by the International Index Erectile Function score (IIEF-5). score from 1 to 4: not interpretable score from 5 to 10: severe erectile dysfunction score from 11 to 15: moderate erectile dysfunction score from 16 to 20: mild erectile dysfunction score from 21 to 25: normal erectile function | 24 months after treatment |
| sexual fonction | Sexual function results are measured by the International Index Erectile Function score (IIEF-5). score from 1 to 4: not interpretable score from 5 to 10: severe erectile dysfunction score from 11 to 15: moderate erectile dysfunction score from 16 to 20: mild erectile dysfunction score from 21 to 25: normal erectile function | 30 months after treatment |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | Day 0, Inclusion |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | 6 months after treatment |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | 12 months after treatment |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | 18 months after treatment |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | 24 months after treatment |
| Evaluation of quality of life | Quality of life measured by EORTC-QLQ-C30. Questions 1 to 28 (general) score from 0 to 4 for each question (not at all to many) Question 29 (health status) score from 1 to 7 (very bad to excellent) Question 30 (quality of life) score from 1 to 7 (very bad to excellent) | 30 months after treatment |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | Day 0, Inclusion |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | 6 months after treatment |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | 12 months after treatment |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | 18 months after treatment |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | 24 months after treatment |
| Evaluation of quality of life | Quality of life measured by PR 25. Questions 1 to 9 (urinary disorders) score from 0 to 4 for each question (none to many) Questions 10 to 13 (intestinal disorders) score from 0 to 4 for each question (none to many) Question 14 (hot flashes) score from 0 to 4 for each question (none to many) Question 15 (gynecomastia) score from 0 to 4 for each question (none to many) Question 16 (swollen legs) score from 0 to 4 for each question (none to many) Questions 17 to 18 (weight gain or loss) score from 0 to 4 for each question (none to many) Questions 19 to 25 (sexuality) score from 0 to 4 for each question (none to many) | 30 months after treatment |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | Day 0, Inclusion |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | 6 months after treatment |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | 12 months after treatment |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | 18 months after treatment |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | 24 months after treatment |
| Evaluation of quality of life | Quality of life measured by the 3-level version of EQ-5D. Questions 1 to 3 (mobility) 1 (no problem) to 3 (unable) Questions 4 to 6 (personal autonomy) 1 (no problem) to 3 (unable) Questions 7 to 9 (current activities) 1 (no problem) to 3 (unable) Questions 10 to 12 (pain/discomfort) 1 (none) to 3 (extreme) Questions 13 to 15 (anxiety/depression) 1 (none) to 3 (extreme) Question 16 (health status) Scale from 0 to 100 (worse health to better health) | 30 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 6 weeks after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 3 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 6 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 12 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 18 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 24 months after treatment |
| The rate of patients in biochemical failure | The rate of patients in biochemical failure is measured by PSA dosage:
| 30 months after treatment |
| The rate of local recurrence | The rate of local recurrence is measured by control biopsy (number of positive biopsies) | 3 months after treatment |
| Survival without metastases | demonstrated by an additional assessment (CT scan and bone scintigraphy, supplemented by MRI in case of suspicious anomaly), recorded on the date of diagnosis. | 6 months after treatment |
| Survival without metastases | demonstrated by an additional assessment (CT scan and bone scintigraphy, supplemented by MRI in case of suspicious anomaly), recorded on the date of diagnosis. | 12 months after treatment |
| Survival without metastases | demonstrated by an additional assessment (CT scan and bone scintigraphy, supplemented by MRI in case of suspicious anomaly), recorded on the date of diagnosis. | 18 months after treatment |
| Survival without metastases | demonstrated by an additional assessment (CT scan and bone scintigraphy, supplemented by MRI in case of suspicious anomaly), recorded on the date of diagnosis. | 24 months after treatment |
| Survival without metastases | demonstrated by an additional assessment (CT scan and bone scintigraphy, supplemented by MRI in case of suspicious anomaly), recorded on the date of diagnosis. | 30 months after treatment |
| Arnas |
| 69400 |
| France |
| Clinique St Etienne | Bayonne | 64100 | France |
| CHRU de Besançon | Besançon | 25000 | France |
| Clinique St Vincent | Besançon | 25044 | France |
| Clinique Tivoli-Ducos | Bordeaux | 33000 | France |
| Clinique St Augustin | Bordeaux | 33074 | France |
| CHU de Bordeaux | Bordeaux | 33076 | France |
| Nouvelle clinique Bel Air | Bordeaux | 33200 | France |
| CHR de Chambéry | Chambéry | 73011 | France |
| Pôle Santé Léonard de Vinci | Chambray-lès-Tours | 37170 | France |
| PôleSanté République | Clermont-Ferrand | 63050 | France |
| Hôpitaux civils de Colmar | Colmar | 68024 | France |
| Polyclinique du parc Drevon | Dijon | 21000 | France |
| CHU de Dijon | Dijon | 21079 | France |
| Cliniqe du Val d'Ouest | Écully | 69130 | France |
| CHU de Grenoble | Grenoble | 38043 | France |
| Hôpital Privé Drome Ardèche | Guilherand-Granges | 07500 | France |
| Cliique du Pré | Le Mans | 72018 | France |
| Clinique Bon Secours | Le Puy-en-Velay | 43000 | France |
| CHRU de Lille | Lille | 59037 | France |
| Clinique La Louvière | Lille | 59042 | France |
| CHU de Limoges | Limoges | 87042 | France |
| Hospices Civils de lyon | Lyon | 69002 | France |
| Hôpital St Joseph | Marseille | 13008 | France |
| AP-AM | Marseille | 13015 | France |
| Clinique Beau Soleil | Montpellier | 34070 | France |
| Clinique Diaconat-Roosevelt | Mulhouse | 68100 | France |
| CHU de Nice | Nice | 06200 | France |
| CHU de Nîmes | Nîmes | 30029 | France |
| Fondation St Jean de Dieu - Clinique Oudinot | Paris | 75007 | France |
| Clinique Turin | Paris | 75008 | France |
| Hôpital St Joseph | Paris | 75014 | France |
| Hôpital TENON | Paris | 75020 | France |
| Institut Mutualiste Montsouris | Paris | 75674 | France |
| Hôpital Europeen Georges Pompidou | Paris | 75908 | France |
| CH de pontoise | Pontoise | 95300 | France |
| Clinique Courlancy | Reims | 51100 | France |
| CHU de rennes | Rennes | 35033 | France |
| Clinique Nantes Atlantis | Saint-Herblain | 44800 | France |
| CH de Saintonge | Saintes | 17108 | France |
| Clinique Rhéna | Strasbourg | 67000 | France |
| Hôpital Foch | Suresnes | 92150 | France |
| Clinique St Michel | Toulon | 83000 | France |
| CHU de Toulouse | Toulouse | 31059 | France |
| Clinique Pasteur | Toulouse | 31076 | France |
| Clinique St Jean du Languedoc | Toulouse | 31400 | France |
| Clinique Océanne | Vannes | 56000 | France |
| CHU de guadeloupe | Pointe-à-Pitre | 97159 | Guadeloupe |
| Ploussard G, Coloby P, Chevallier T, Occean BV, Houede N, Villers A, Rischmann P; HIFI group. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025 May;87(5):526-533. doi: 10.1016/j.eururo.2024.11.006. Epub 2024 Dec 4. |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided